He was tired of just surviving. A pig kidney gave him a shot at living
Tim Andrews' wife, Karen, said she "started bawling like a baby" after his successful pig kidney transplant.
Tim Andrews knew that he needed dialysis to manage his end-stage kidney disease, but over months of treatment, he started to wonder whether it was worth it. He was exhausted and hopeless. He missed his grandkids.
It kept him alive, but it didn't feel like living.
Desperate for another option, he found a surprising alternative: an organ from a pig.
Andrews, 67, is a pioneer of a new kind of medicine. In January, he had an experimental cross-species transplant of a kidney from a genetically modified pig. He is one of only a handful of patients who have undergone the experimental procedure. For now, he's the lone person in the United States known to be living with a pig kidney.
Andrews knew that there was a risk to trying something so new, but if the kidney gave him just one more day free from dialysis, it was worth it — for him and for fellow patients.
'This will do something for humanity,' Andrews said.
'Pick a box'
Andrews had been living with diabetes since the 1990s, managing the condition with insulin. About 2½ years ago, he went to the doctor feeling unusually tired. Tests showed that he had stage 3 kidney failure — his kidneys were still working but less efficiently than they should. He was relieved to learn that it was manageable with medication, monitoring and lifestyle changes.
But about a month later, a doctor delivered more bad news: Andrews' kidney disease had rapidly progressed to end-stage disease. Dialysis was the only option to keep him alive until he could get an organ transplant.
Dialysis is highly effective at cleaning the blood, but it places a 'huge burden' on the body, Andrews' doctors told CNN. At first, Andrews thought it was going well. But about six months in, he had a heart attack.
'It takes a toll on you, emotionally and physically,' said Andrews, who lives in New Hampshire.
He was tempted to forgo dialysis entirely until a doctor warned that if he did so, he should 'pick a box.' With the state his kidneys were in, his body would be in it within a couple months.
For six hours, three days a week, he kept at it. On days off, he'd sleep. By the time he woke up, he'd have to start the process all over again.
When he thinks about his experience with dialysis, Andrews appreciates what the doctors and nurses did to keep him alive. But when he kept having to sit in that oversized green chair hooked up to the dialysis machine, the whole situation hurt his spirit, too.
He was too tired to walk or get groceries. He couldn't eat. Even in the few hours he felt OK, his immune system was so weak that he had to avoid crowds. Dialysis meant no more Red Sox games, no more fun with grandchildren, no more travel.
As the hours ticked past, he couldn't think about gratitude. All he could think about was death.
The dialysis side effects got so bad that he wanted to quit, but his wife, Karen, wouldn't let him. He also kept hearing his father's voice in his mind, telling him to stop complaining and start doing something about his situation.
'I know what end-stage means'
Andrews learned that his odds of getting a human kidney donation were not good.
Nearly 90,0000 people are on the waiting list for a kidney in the US. Most don't get a transplant because they become too sick or die while waiting for a match.
Andrews' chances were slimmer than most because of his rare blood type. People typically wait about three to five years for a donor kidney. For him, it would likely be seven to 10 years. Doctors thought his body could take only five years of dialysis.
'I was a little short there,' Andrews said. 'I know what end-stage means.'
But his research gave him hope. Massachusetts General Hospital was also investigating animal alternatives. He demanded that the hospital liaison put him in touch with one of the doctors from that project: Dr. Leonardo Riella, medical director of kidney transplantation at Mass General.
When they first met, Andrews was 'very frail,' Riella said. He arrived in a wheelchair. But when Riella mentioned what's known as xenotransplantation — transplants using genetically modified pig organs — Andrews' eyes 'sparked.'
'He said 'Tell me what I need to do.''
Riella told Andrews he'd need to get a lot stronger if he wanted a transplant of any kind.
'They said, 'Prepare your body for battle,' ' Andrews' wife, Karen, remembered.
For the next few months, Andrews went to the gym and physical therapy, got his teeth fixed, got several vaccines and lost 22 pounds.
When he went back to the clinic a few months later, Riella said, Andrews was 'almost running around the room.'
He talked to people about the procedure. He prayed. His wife, Karen, also had to agree: If they got the green light, she would need to sign consent papers. On the slim chance he got a virus from the organ, she'd be exposed to it, too.
'I was a little taken aback by that,' Karen said. But she didn't have any doubt that this transplant, though unusual, was the right way to go.
'It has to be better than dialysis,' she said. 'He was just feeling so awful all the time.'
A new birthday
In January, it was finally time.
On surgery day, his family hugged and kissed him good-bye. Karen gave him a high-five and wished him luck.
The procedure was supposed to take four hours, but only about two hours and 15 minutes in, Karen said, her phone rang. The doctors were done early and said it went 'unbelievably well.'
A team of doctors told Karen that they had successfully attached the genetically modified pig kidney alongside Andrews' nonfunctioning organ.
'They put the kidney on the table and started connecting him to the kidney, and he actually peed across the room,' Karen said, laughing. Everyone in the operating room started cheering.
'Of course, I started bawling like a baby,' Karen said.
It all happened so fast that even the doctors who did the surgery were surprised.
'It worked right away, and the numbers started getting better,' Riella said.
After waking up from surgery, Andrews felt 'reenergized and revitalized.'
'I was alive, and I hadn't been in a long time,' he said.
He hopped off the bed and tap-danced across the room, he said. His mind felt clear.
'It was a miracle,' Andrews said. So much so, he declared that he had a new birthday.
'I said 'look at me, it's like I'm like a new man,' ' he said. 'It's like new birth. I said, 'I've got a new birthday. 1/25/25 is my new birthday.' '
'Now I can do anything I want'
After the transplant, Andrews spent a week in the hospital but only out of an abundance of caution.
In the months since, he's had a few 'small bumps in the road,' including a three-week hospital stay. But the pig kidney does what a kidney from a living human donor would do.
Life is returning to normal. Andrews cooks, vacuums and takes long walks with his dog, Cupcake.
He currently takes more than 50 pills every day as the doctors try to figure out the type of medications he'll need with his new kidney. But living without dialysis has made such a difference.
'Basically, I was just sleeping, sick all the time. Now I can do anything I want,' Andrews said.
He even lets himself picture a future. He can't wait to see his grandkids again.
'They saw me at the lowest, and now they'll be able to see me alive and laughing and carrying on like Grandpa does,' Andrews said.
If all goes well, he hopes to take Karen to Europe in a year. He said they've put it off far too long.
'It's a learning curve'
Still, Andrews knows that the pig kidney may not work long-term. He's still on the wait list for a human organ. If the pig kidney can act as a bridge that keeps him healthy enough to wait for a match from a human donor, that would be a medical first — and a success.
Andrews is the fourth living patient in the US to get a genetically modified pig kidney transplant, and he won't be the last. In addition to the ongoing trial at Mass General in conjunction with biotech firm eGenesis, United Therapeutics Corp – the other main biotech company helping create the pig kidneys – announced in February that it would be allowed to start its own clinical trials with New York University.
In March 2024, Richard Slayman became the first living patient in the world to get a genetically modified pig kidney. The operation at Mass General went well, but he died two months later from causes not related to the transplant.
Doctors said they learned a lot from their experience with Slayman. He had scarring on his heart after eight years of dialysis, Riella said, and it's probably important to get patients like Andrews, who haven't needed dialysis as long.
In April 2024, Lisa Pisano became the first person to receive a mechanical heart pump as well as a gene-edited pig kidney. The organ failed due to limited blood flow and was removed the next month. She died in July 2024.
Then, in November 2024, NYU transplanted 53-year-old Towana Looney with a genetically modified pig kidney. It functioned for four months and nine days, the longest yet, but doctors had to remove it in April when her immune system started to reject it.
Figuring out how to manage rejection is going to be key, doctors say. The pig kidneys Andrews and Slayman got had 69 genomic edits, while Looney's had fewer. Doctors say they still don't know how many edits are necessary, but both versions of the modified pig kidneys had pig genes removed and human genes added to make the organ more compatible with the human body.
Patients also receive anti-rejection drugs and wearable remote monitoring tools. But doctors still are figuring out how much medicine and monitoring is needed.
'It is a learning curve,' Riella said.
Riella is hopeful xenotransplantation may one day solve the world's organ shortage.
'I think patients like Tim will be remembered as heroes,' he said. 'Without them willing to take the risk, we wouldn't be able to move this to the clinic.'
Andrews remembers what it felt like to have to make the choice. But he also remembers what it was like to sit for hours at the dialysis center.
'It's hard to come to terms with mortality. You think 'ah, I can handle that' and everything, but it's tough,' he said recently, back in the green chair where he underwent dialysis. 'It was very tough to realize that was it.
'I was going to die in this building.'
He found a way out. He hopes his story will inspire others to look for hope, too.
'I see way too many people give up,' Andrews said. 'Don't give up.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
an hour ago
- Globe and Mail
Luxenberg Garbett Kelly & George P.C. Discusses Medical Deadlines Following a Workplace Injury
Western Pennsylvania workers' compensation lawyers at Luxenberg Garbett Kelly & George P.C. ( have released vital guidance on the importance of promptly seeking medical treatment following a workplace injury. The article, titled 'How Long Do I Have to See a Doctor After a Work Injury?', highlights how timing can significantly affect both health outcomes and the ability to obtain workers' compensation benefits. According to the article, any delay in receiving medical care after a workplace accident may jeopardize a claim. Western Pennsylvania workers' compensation lawyers stress that while the law may not define a strict deadline to visit a doctor, early medical attention serves as key documentation that links the injury to the workplace. 'Even if the injury seems minor at first, delaying treatment can lead to complications and make it harder to prove that your condition is work-related,' the firm notes. Western Pennsylvania workers' compensation lawyers at Luxenberg Garbett Kelly & George P.C. point out that Pennsylvania law requires injured workers to report incidents within 120 days, though it is strongly recommended to do so as soon as possible. Reporting immediately not only initiates the claims process but can also help direct injured employees to approved medical providers if necessary. Failure to notify an employer or seek prompt care may result in a disputed or denied claim. The firm's article outlines that if an employer in Pennsylvania has a posted list of at least six approved healthcare providers, the injured employee must receive treatment from one of these providers for the first 90 days. During this time, claimants retain the freedom to choose from the list but may not receive compensation for out-of-network treatment. Once this 90-day period ends, injured workers may switch to a physician of their choice, provided that the employer is notified. Delays in treatment may also open the door for insurance companies to argue that an injury did not occur at work or is not severe enough to warrant compensation. The article provides cautionary insights into how insurers use gaps in medical treatment to question the legitimacy of claims. It notes that some injuries, including internal damage or soft tissue injuries, may not show immediate symptoms but can worsen without prompt medical care. Luxenberg Garbett Kelly & George P.C. also covers the topic of Independent Medical Examinations (IMEs), which are conducted by employer-selected physicians. These evaluations do not replace treatment but are used to determine whether a claimant is still eligible for benefits. If a worker refuses to attend an IME, their benefits may be suspended by court order. For individuals who delayed seeking care, the article advises immediate action. It encourages injured workers to make medical appointments, clearly inform physicians that the injury was job-related, and explain any delays. It also recommends gathering supporting evidence such as witness statements, written communication, and internal records to help support the claim. A key quote from the article reads: 'Workers' compensation may deny or limit your claim if you don't seek medical attention quickly. Not getting treatment right away may be seen as evidence that the injury wasn't serious or didn't happen at work, giving the insurer grounds to reject your claim.' The article concludes by explaining scenarios in which legal assistance from a workers' compensation attorney can be critical. These include denied or delayed claims, employer pressure to see specific doctors, retaliation following a report, or disputes involving pre-existing conditions. The firm outlines how legal support may help claimants secure necessary care and wage replacement without unnecessary complications. Delays in treatment not only compromise physical recovery but also make it more difficult to connect the injury to the workplace and gain approval for benefits. Workers must act swiftly, follow correct procedures, and maintain accurate records to strengthen their claim. When necessary, involving legal representation can help address disputes and streamline the claims process. For those injured in Western Pennsylvania, Luxenberg Garbett Kelly & George P.C. offers guidance and representation in navigating the often-challenging workers' compensation system. Their team provides direction on legal timelines, reporting requirements, and medical documentation to help claimants pursue the benefits they need. About Luxenberg Garbett Kelly & George P.C.: Luxenberg Garbett Kelly & George P.C. serves injured workers across Western Pennsylvania with legal support in workers' compensation matters. The firm represents clients in disputes over denied claims, medical access issues, and benefits delays, working to protect the rights of injured employees throughout the region. Embeds: Youtube Video: GMB: Email and website Email: lmkelly@ Website: Media Contact Company Name: Luxenberg Garbett Kelly & George P.C. Contact Person: Lauren Kelly Gielarowski Email: Send Email Phone: (724) 658-8535 Address: 315 N Mercer St City: New Castle State: Pennsylvania 16101 Country: United States Website:


CTV News
an hour ago
- CTV News
‘We think we understand, but we don't': Registered psychologist gives tools to help victims of domestic violence
According to Stats Canada, cases of intimate partner and family violence are higher in Alberta than the national average. Registered psychologist Lisa Rowbottom joined CTV Morning Live's Kent Morrison for tools on navigating important, but difficult conversations. This transcript has been edited for length and clarity. Kent Morrison: If you know someone who is a victim of domestic violence, let's start with what you should not do. Lisa Rowbottom: The number one thing you should not do is get frustrated and withdraw. People don't realize that there's a lot of psychological mechanisms involved and a lot of manipulation, and it can take a long time for the person to be able to get out of the relationship. Oftentimes, people get frustrated and they start giving the person an ultimatum, like if you don't stop talking to them or you don't get away from them, then they're never going to talk to you again. When you do that, you push the person into the arms of their abuser because they no longer have any other options of people they feel might care. Kent: So it may feel like tough love from a loved one, but that's not going to be the right strategy? Lisa: If you think about how counterintuitive it is to stay in a relationship with someone who is verbally, physically, psychologically abusing you. We think we understand what it's like to be in that situation but we truly don't. Kent: What are healthy ways we can help? Lisa: The first thing to do is to do some research. Read some information, read some accounts of people who were in those relationships, so you can help yourself understand what's actually going on. Then you should spend some time gathering resources because often the person in the relationship doesn't have the time or is too scared to actually go about getting any sort of resources around and getting out. I think the most important thing is to keep in mind the person that you meet, when you meet the abusive partner, is not necessarily the person that the abused partner encounters at home. If the partner comes to you and says, 'this person is abusing me,' sometimes the first instinct is to try and defend the other person because your experience of them is that they're not abusive. It's most important that when the person comes to you, you believe them, whether that's your experience or not. Kent: Are there any other healthy techniques that people can deploy to try to help someone they know or someone that's not necessarily a close friend, but you witness something? Lisa: If you're witnessing it happen in the moment, you can and should call emergency services if you're witnessing somebody being hurt. If you have more of a distant relationship with the person, you can provide them with information and resources. The Government of Canada has a website with a list of a lot of general resources and it's broken down by province, so it's a pretty easy Google search. If you just say, 'I have a concern, here's a number that you can call if you want any more information,' or, 'if there's anything else that I can help you with, here's a number you can call.' Then step back as much as you can because it'll be the person's close friends that will have to be the ones to have those hard conversations.


Globe and Mail
4 hours ago
- Globe and Mail
Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space
Mergers and Acquisitions (M&A) have picked up significant pace in 2025 in the pharma/biotech sector after a passive run in 2024. The recent spree of acquisitions signifies a focus on portfolio expansion and constant pipeline innovation, given the changing landscape and spotlight on AI-driven drug discovery. Simultaneously, bigwigs in the space also enter into licensing deals and collaborations for a promising drug/candidate to strengthen and expand their portfolios in their respective core areas. Quick Take on Recent Acquisitions & Deals Pharma giant Sanofi SNY recently announced that it will acquire Blueprint Medicines for a total deal value of up to $9.5 billion to expand its portfolio in rare immunological disease and add an early-stage pipeline in immunology. The impending acquisition will add Blueprint Medicines' only marketed product, Ayvakit (avapritinib), an inhibitor of KIT and PDGFRA proteins, to Sanofi's commercial portfolio. Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech for the global co-development and co-commercialization of the latter's investigational bispecific antibody BNT327 across numerous solid tumor types. BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. Per the terms, BMY will make an upfront payment of $1.5 billion to BioNTech. In addition, BioNTech will also receive $2 billion in non-contingent anniversary payments through 2028. Developing bispecific antibodies that target two proteins, namely PD-1 and VEGF, has lately been one of the lucrative areas in cancer treatment, attracting other pharma giants as well. In May 2025, Pfizer inked a licensing agreement with 3SBio for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside China. While oncology and immuno-oncology companies have always been at the top of acquisition targets, the lucrative obesity sector and gene-editing space are also being eyed. Last week, Regeneron REGN entered into an in-licensing agreement for an obesity drug with Hansoh Pharmaceuticals Group Company Limited, in a bid to expand its clinical-stage obesity portfolio. The licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist. M&A in Focus in 2025 Consolidation has long been a central focus in the pharma/biotech industry. This is because leading companies constantly look to diversify their revenue base in the face of dwindling sales of their high-profile drugs. Acquisitions also make sense as developing a drug/technology from scratch is costly and risky. In April, pharma giant Johnson & Johnson acquired Intra-Cellular Therapies for approximately $14.6 billion and added antidepressant drug, Caplyta, to its neuroscience portfolio. Swiss pharma bigwig Novartis NVS, too, has been on an acquisition spree. Novartis is all set to acquire San Diego-based clinical-stage biopharmaceutical company Regulus Therapeutics to strengthen its renal disease portfolio. Regulus' lead asset, farabursen, is a potential first-in-class, next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. In April, Germany-based Merck KGaA announced that it will acquire SpringWorks Therapeutics, Inc. for $3.9 billion to expand business in the United States. SpringWorks Therapeutics, a U.S.-based biopharma company, has a portfolio that comprises a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas. Potential Deals We expect M&A activity to accelerate further in 2025, given the massive cash reserve owned by major pharma and biotech companies. These companies will also look to utilize innovative technology to develop breakthrough treatments rapidly as the landscape evolves. Moreover, smaller biotechs often lack the necessary funds to successfully develop a drug and commercialize thereafter. The recent spotlight on the usage of AI technology for drug discovery should lure investment in this industry. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report